Business Update

Heska announces sale of allergy patent portfolio

Published in Biotech Law Weekly, February 23rd, 2007

Heska Corp. (HSKA) announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Allergopharma Joachim Ganzer, KG, for an undisclosed sum.

As part of the agreement, Heska Corp. has exclusively licensed veterinary rights to the portfolio.

"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."

"We are committed to being a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2007-02-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry